An Italian company that in the past joined the fight against Ebola has signed an agreement with Oxford University to develop a vaccine for coronavirus.
The Oxford-AstraZeneca vaccine is one of 150 in development globally, but is considered the most advanced.
First trial results suggest that the vaccine produces a good immune response in volunteers without serious side-effects.
Euronews spoke to the Managing Director of the Italian company that worked on the project. Giorgia Orlandi reports.